Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Blocking New Blood Vessel Formation Cures Alzheimer's Disease in Mouse Model

By BiotechDaily International staff writers
Posted on 21 Mar 2013
Vaccination of mice with a syndrome that mimics human Alzheimer's disease (AD) with amyloid-beta protein normalized the production of bloods vessels in the brains of the animals and eliminated the accumulation of amyloid plaque.

Investigators at the University of British Columbia (Vancouver, Canada) worked with the Tg2576 mouse AD model. In addition to the characteristic amyloid-beta (A-beta) plaques that characterize the brain in AD, these animals displayed an abnormal number of brain blood vessels. Some of these blood vessels were incomplete and caused leakiness in the blood-brain barrier (BBB).

The investigators immunized a group of Tg2576 mice with peptides derived from the amyloid-beta protein. They reported in the February 28, 2013, online edition of the journal Scientific Reports that immunization with A-beta peptides neutralized the amyloid trigger leading to formation of new blood vessels and reversed the abnormal number of these vessels in the Tg2576 AD mice. Reduction in number of blood vessels resolved the animals' plaque burden, suggesting that formation of new blood vessels (neoangiogenesis) was a key mechanism underlying plaque formation.

“The discovery provides further evidence of the role that an overabundance of brain blood vessels plays in AD, as well as the potential efficacy of amyloid-beta as basis for an AD vaccine,” said senior author Dr.Wilfred Jefferies, professor of medical genetics at the University of British Columbia. “Now that we know blood vessel growth is a factor in AD, if follows that drugs targeting blood vessels may be good candidates as an AD treatment.”

Related Links:
University of British Columbia



Channels

Biochemistry

view channel

Possible New Target Found for Treating Brain Inflammation

Scientists have identified an enzyme that produces a class of inflammatory lipid molecules in the brain. Abnormally high levels of these molecules appear to cause a rare inherited eurodegenerative disorder, and that disorder now may be treatable if researchers can develop suitable drug candidates that suppress this enzyme.... Read more

Therapeutics

view channel
Image: Cancer cells infected with tumor-targeted oncolytic virus (red). Green indicates alpha-tubulin, a cell skeleton protein. Blue is DNA in the cancer cell nuclei (Photo courtesy of Dr. Rathi Gangeswaran, Bart’s Cancer Institute).

Innovative “Viro-Immunotherapy” Designed to Kill Breast Cancer Cells

A leading scientist has devised a new treatment that employs viruses to kill breast cancer cells. The research could lead to a promising “viro-immunotherapy” for patients with triple-negative breast cancer,... Read more

Lab Technologies

view channel
Image: MIT researchers have designed a microfluidic device that allows them to precisely trap pairs of cells (one red, one green) and observe how they interact over time (Photo courtesy of Burak Dura, MIT).

New Device Designed to See Communication between Immune Cells

The immune system is a complicated network of many different cells working together to defend against invaders. Effectively combating an infection depends on the interactions between these cells.... Read more

Business

view channel

Program Designed to Provide High-Performance Computing Cluster Systems for Bioinformatics Research

Dedicated Computing (Waukesha, WI, USA), a global technology company, reported that it will be participating in the Intel Cluster Ready program to deliver integrated high-performance computing cluster solutions to the life sciences market. Powered by Intel Xeon processors, Dedicated Computing is providing a range of... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.